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Abstract
Background: Molecular DNA cloning is crucial to many experiments and with the trend to higher throughput of
modern approaches automated techniques are urgently required. We have established an automated, fast and
flexible low-cost expression cloning approach requiring only vector and insert amplification by PCR and
co-transformation of the products.
Results: Our vectors apply positive selection for the insert or negative selection against empty vector molecules
and drive strong expression of target proteins in E.coli cells. Variable tags are available both in N-terminal or
C-terminal position. A newly developed b-lactamase (ΔW290) selection cassette contains a segment inside the
b-lactamase open reading frame encoding a stretch of hydrophilic amino acids that result in a T7 promoter when
back-translated. This position of the promoter permits positive selection and attenuated expression of fusion
proteins with C-terminal tags. We have tested eight vectors by inserting six target sequences of variable length,
provenience and function. The target proteins were cloned, expressed and detected using an automated Tecan
Freedom Evo II liquid handling work station. Only two colonies had to be picked to score with 85% correct inserts
while 80% of those were positive in expression tests.
Conclusions: Our results establish co-transformation and positive/negative selection cloning in conjunction with
the provided vectors and selection cassettes as an automatable alternative to commercialized high-throughput
cloning systems like Gateway® or ligase-independent cloning (LIC) .
Background
The use of recombinant DNA technologies is nowadays
spread through most laboratories conducting research in
life sciences and the applications, including gene expres-
sion systems, tend towards being more parallelized. The
classical protocols to join DNA fragments by restriction
and ligation as well as most techniques employing
recombination depend on the presence of specific short
sequences at or around the joining regions. However,
only completely unrestricted sequence joining will permit
us to construct the desired DNAs exactly the way we
imagine. The techniques to achieve this are pretty much
available today [1,2] and include use of homologous
recombination in intact cells [3,4] as well as enzyme mix-
tures to join the vector and insert DNA in vitro (commer-
cialized enzyme mixes like In-Fusion, Clontech or ClonEZ,
Genscript). Mating-assisted genetically integrated cloning
(MAGIC, [3]), the perhaps most elegant of the in vivo
systems, is currently not far enough developed to be
broadly applicable and the in vitro systems that are dis-
tributed by companies are expensive.
The original success with a cloning system employing
positive selection [for a review, see [5]] after in vivo
recombination of inserts in a specific expression vector [4]
encouraged us to develop a series of expression vectors
relying on a positive or negative selection principle. A
positive selection for the insert results whenever the clon-
ing leads to the creation of an additional resistance. The
term ‘negative selection’ is used here to describe cloning
systems with vectors that contain the ccdB cell-death gene
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which is replaced by the cloned insert, i.e. the selection
eliminates the vector molecules without insert.
Because the trend to parallelization calls for automata-
ble techniques we developed a very robust cloning sys-
tem that is fully automatable. The initial expression
screening of the eight vectors was carried out with
enhanced green fluorescent protein and scored positive
for all of them (data not shown). In the following, auto-
mated cloning and expression screening was conducted
with six different target proteins which were known to
us to be well expressed. The cloning and expression
procedures proved exceptionally robust and all vectors
showed high expression comparable to commercially
available T7 vectors.
Methods
Vector and insert DNA preparation
All PCR primers were synthesized by Microsynth (Bal-
gach, Switzerland) and used without further purification.
Oligonucleotide sequences and uses are given in Figures
1 and 2, respectively. Template DNA for PCR was pre-
pared by extraction from transformed Mach1 cells or
ccdB survival cells (Invitrogen, Rotkreuz, Switzerland)
using the GeneJet DNA minipreparation kit (Fermentas,
Vilnius, Lithuania). About 2 ng of DNA were used as
template for PCR. We used Phusion® polymerase (Finn-
zymes Oy, Espoo, Finland) as described [6]. Most proof-
reading DNA polymerases may be used, however, it is
vital to avoid polymerases with terminal transferase activ-
ity like Taq that lead to A-tailing of the 3′ ends of the
PCR product. Before co-transformation both vector and
insert were linearized by PCR. The excess of primers was
removed by reaction cleanup on Minelute columns (Qia-
gen, Hilden, Germany). For vector preparations requiring
more DNA, several PCR reactions were pooled and puri-
fied on larger spin columns (25 μg capacity, Fermentas,
Vilnius, Lithuania). In general, cloning success depends
on quality of the PCR product which should show a sin-
gle band on agarose gel after electrophoresis. Gel purifi-
cation of the PCR product and digestion of the templates
with DpnI are not necessary (unless a template plasmid
carries both resistances).
Co-transformation cloning using E.coli Mach1 cells
All plasmids were constructed by in vivo joining of PCR
products with overlapping ends (about 15 bp) by a tech-
nique which we call co-transformation cloning. The
E.coli strain Mach1 yields most colonies, but a few other
strains like DH5alpha and Top10 work also. Co-
transformation employs chemically competent cells [7]
yielding 107 or more colonies per μg plasmid. Per co-
transformation 200 ng of vector plus 50-500 ng of insert
were mixed and the competent cells added to the DNA
mixture which was less than 10% of the cell volume
(50 μL cells). The protocol is standard: 30 minutes on
ice, 45 s at 42°C, 1 min on ice and then addition of 4
volumes SOC medium [8]. In contrast to other proto-
cols, a longer recovery time of 2 h was necessary to
complete the end joining reaction before antibiotic
selection was applied (Figure 2). Co-transformation
works well with inserts up to 1.5 kb length. For longer
inserts or cloning without positive or negative selection
we use the ClonEZ kit (Genscript, Piscataway, NJ, USA).
Automation and general molecular biology techniques
All experimental procedures were carried out using a
TECAN Freedom Evo II liquid handling workstation.
The only procedures performed by hand were colony
picking and insert DNA purification with the Qiagen
Minelute reaction cleanup kit which are, however, both
automatable (Reference [9], Qiacube from Qiagen).
The basic techniques applied for construction of the
vectors (not described in detail) are from the Molecular
Cloning Handbook [8]. DNA fragments were analyzed by
fast agarose gel electrophoresis [10,11]. DNA restriction
or modification enzymes were from Fermentas (Vilnius,
Lithuania) or New England Biolabs (Ipswich, MA, USA).
For colony-PCR the Go-Taq Mastermix from Promega
(Madison, WI, USA) was used. Cells were spread on agar
plates by shaking on the TECAN workstation. Two colo-
nies per target were picked and inoculated into 3 mL of
2xTY media with antibiotics. The cells were grown over-
night at 37°C and spun down at 1900 rpm for 10 min.
The plasmids were prepared on our TECAN workstation
using the NucleoSpin Robot 96 Plasmid Kit. The plasmid
was eluted with 200 μL of elution buffer and the yield
was quantified by UV absorption.
Protein expression
All methods were carried out based on standard proto-
cols [8] and are briefly described: The expression plas-
mids were transformed into E. coli expression strains
(BL21(DE3) for EB1, Clip170-CapGly, TTL, CLIP170-
full, PKNG and Acella for AAV2-VP3, respectively) and
Figure 1 Sequences of primers for vector amplification. For use
of primers, see figure 2.
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selected on LB-agar plates with antibiotics. Pre-cultures
were grown over night at 30°C in deep 24-well blocks
inoculating 4 mL LB. Expression cultures were started
the next day by adding 200 μL pre-culture to 4 mL LB
media. The cultures were grown at 37°C until the OD600
reached 0.4 and then moved to a 20°C incubator. The
expression was induced 30 min later with 1 mM IPTG
for Clip170-CapGly, EB1, CLIP170, VP3 and TTL or 0.1
mM IPTG for PKNG. The cells were harvested after
overnight growth at 20°C.
The 4 mL cultures were pelleted and resuspended into
1 mL lysis buffer (50 mM HEPES pH8, 500 mM NaCl,
10% glycerol, 10 mM imidazole). The cells were lysed by
sonication. The cell extracts were centrifuged for 10
min at 15,000 × g at 4°C. The soluble fractions were
loaded onto 400 μL NiNTA IMAC resin (Ni Sepharo-
seTM High Performance, GE Healthcare) in a 96 well
filter plate (Novagen) pre-equilibrated with HEPES pH8,
500 mM NaCl, 10% glycerol, 10 mM imidazole. The
beads were washed 3 times with 1 mL of the above buf-
fer and the proteins eluted with 200 μL 50 mM HEPES
pH8, 500 mM NaCl, 10% glycerol, 500 mM imidazole.
The purified proteins were analysed by SDS-PAGE and
Western blotting with anti-penta His antibodies
(Qiagen).
Results
Basic strategies and development of cloning vectors
Three strategies are used to achieve positive selection for
the target insert (Figure 3) by creating a new antibiotic
resistance which is coupled to the correct orientation and
terminal sequence of the insert DNA. A fourth strategy is
applied to get negative selection against the vector back-
bone which contains the ccdB cell death gene that is
removed during the cloning procedure. The vectors per-
mit a high level of target expression in E.coli (Figure 4)
and are mostly derivatives of pET47b (PSTCm1, PSPCm2,
PSTCm8, PSTCm10, PSPCm11, NSKn1). Several of the
vectors come in two versions, one with an N-terminal
thrombin- and the other with a prescission-protease clea-
vage site downstream of the his6-tag. This is achieved
by amplifying the same template plasmid with different
primer sets. In one of the vectors, the his6- tag is
positioned C-terminally of the target protein. The
Figure 2 Features of expression vectors. All vectors except PSAP1 (backbone is pQE80L, Qiagen, Hilden, Germany) and PSKn1 (backbone is
pET28c, Novagen, San Diego, CA, USA) are derived from pET47b (Novagen). Start and Stop primers are used to linearize the vectors for insertion
of target sequence by co-transformation. The overlaps with the target PCR are indicated. The sequences of the vector template plasmids are
available on request. The nomenclature permits fast recognition of the features of the vectors: The names start with PS for positive selection
with chloramphenicol (Cm80 = Chloramphenicol 80 mg/L), ampicillin (Amp) or kanamycin (Kan) and NS, for negative selection with ccdB,
respectively. The proteolytic cleavage site is indicated by T for thrombin and P for prescission proteases. The tag(s) are indicated and finally the
antibiotic resistance is given followed by a number. The concentration of the antibiotics can vary greatly depending on the vector’s copy
number per cell.
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additional thioredoxin- and RNAse S-tags are intended to
increase the yield of expression [12].
The construction of new vectors relies on the inser-
tion of a selection cassette as amplified from one of the
expression constructs. We can complement three differ-
ent defective antibiotic resistance genes for insert
selection with chloramphenicol, kanamycin or ampicillin
(Reference [4] and Figure 3, see also ‘Additional file 1’
for nucleotide sequences of the vectors). For example,
the chloramphenicol selection-cassette was amplified
such as to contain the CAT gene plus its active promo-
ter including the -30 TTGACA sequence [13] and
Figure 3 Schemes of applied insert selections. For each selection type one vector example is shown. Positive selection with chloramphenicol:
Vector with inactive promoter, upon insertion of target the -35 box is introduced and the promoter is active. Positive selection with kanamycin:
By insertion of the target PCR a new C-terminal Phe residue is introduced which activates the kanamycin kinase. Wild Type kanamycin kinase has
two Phe residues at the C-terminus. Positive selection with ampicillin: Similar to the kanamycin selection, the missing C-terminal Trp residue of
beta-lactamase is complemented by the insert cloning. Negative selection with ccdB: The cassette with the cell killer gene ccdB is replaced by
the desired insert.
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Figure 4 High expression levels are reached with most of the vectors. The cell pellets from expression cultures were extracted with SDS-gel
sample buffer and run on 12% SDS_PAGE. From left to right: Mr markers; 1, PSTCm1-EB1; 2, PSPCm2-VP3; 3, PSTCm8-CapGly; 4, PSTCm8-TTL; 5,
PSTCm11-CapGly; 6, PSKn1-Clip170; 7, NSkn1-EB1. The desired expression product is represented by the strongest band in the corresponding
lane with the total cell extract. Only the vector PSAp1 gave less vigorous expression (not shown).
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inserted into the vector backbone. The desired tag was
also inserted by PCR-mutagenesis using two primers to
amplify the whole plasmid along with the tag sequence.
The primers are designed to create 15 bp of identical
sequence in the region of the tag at each end of the lin-
ear PCR product. The PCR product is digested with
Dpn I and transformed into E.coli Mach1 cells. These
cells can circularize the plasmid by recombination of the
short terminal repeats at the ends of the PCR product.
This kind of mutagenesis is efficient; more than 90% of
the clones are correct. If two DNA fragments have to be
joined, corresponding overlaps are designed at the ends
of the fragments which are co-transformed into Mach1
cells.
The vector PSAp1 is derived from pQE80L (Qiagen)
and permits positive selection with ampicillin for a tar-
get with C-terminal tag fusion. In order to activate the
silent chloramphenicol acetyl transferase gene in
pQE80L, the lambda terminator downstream of the T5
promoter was deleted. This version of pQE80L became
resistant to chloramphenicol in presence of 0.5 mM
IPTG. The plasmid was amplified with two primers
(#1407 and #1408) containing a T7 promoter sequence
in the 5′ attachments to the annealing region. The inser-
tion occurs into the second C-terminal loop of beta-lac-
tamase (see 3D-structure NCBI structure database,
molecule 1BTL). The reading frame in the T7 promoter
sequence region was chosen such as to encode hydro-
philic amino acids. The PCR product was digested with
Dpn I and transformed into Mach1 cells. After verifying
this mutagenesis by DNA sequencing, a positive clone
was tested for ampicillin resistance, which proved to be
similar to the wild type plasmid. Several other con-
structs with promoter insertions using different borders
or insertions in the first C-terminal loop or split gene
approaches led to inactivation of beta-lactamase. The
plasmid with ampicillin resistance was amplified with
two primers (#1470 and #1471) in order to introduce a
C-terminal His6- tag and to delete the C-terminal tryp-
tophan residue of b-lactamase (called ΔW290). This
plasmid is designated #790, is ampicillin-sensitive and
used as a template to amplify the linear positive selec-
tion vector PSAp1. As opposed to the situation shown
in Ref. [4] the b-lactamase gene is located upstream of
the insert and has the same orientation as the insert.
This is possible because of the newly inserted T7 pro-
moter which was engineered into the b-lactamase gene
and which now drives the expression of the target.
Because the T7 promoter lies within a transcribed gene,
it is less vigorously active than a T7 promoter in a non-
transcribed region of a standard T7 expression vector.
Although we have observed about 10 fold lower expres-
sion levels with this vector compared to standard T7
vectors, it may come in handy if attenuated target
expression is desired, e.g. for expression of membrane
proteins.
Negative selection in the vector NSKn1 is due to a
ccdB cell death gene in the vector which has to be
grown in ccdB survival cells. The sequence of the inser-
tion including the ccdB gene is given in the ‘Additional
file 1’. This toxic gene is replaced by the insert protein;
the construct grows now in Mach1 cells. A primer pair
is used to amplify the linear vector excluding the ccdB
gene (Figures 1 and 2, primers 1437 and 1438). This
vector backbone is then co-transformed with the insert
DNA which overlaps with the vector ends at the termini
of the PCR fragment. The pET47b-derived vector was
linearized by PCR (primers #1410 and #1411). The ccdB
cassette with the appropriate ends was optimized for
expression in E.coli using the Gene Designer program
(DNA 2.0 Inc.) and synthesized by Genscript. This DNA
(790 bp sequence, see ‘Additional file 1’) was PCR-
amplified (primers #1412 and #1413) and joined with
the vector by treating with the ClonEZ kit (Genscript)
and transformed into ccdB survival cells because the
ccdB survival cells were not able to recombine the PCR
products upon co-transformation.
The only vector employing positive selection by kana-
mycin has a backbone from the plasmid pRSF (Merck
Biosciences), is streptomycin resistant and can be trans-
formed and maintained in an E.coli strain which simulta-
neously harbors a second plasmid with a colE1 origin like
the pET-derivatives using chloramphenicol or the pQE80
derivative using ampicillin for selection. Therefore two
proteins can be co-expressed in the same host cell.
Construction of expression plasmids by co-transformation
All vectors and inserts were linearized by PCR on a
TECAN workstation using 96-well microtiter plates.
The PCR products display a set of standardized cloning
overhangs, usually a sequence encoding the proteolytic
cleavage site and another one in the positive selection
region of the vector. Some of the eight vectors share the
cloning overhang pairs (Figure 1), i.e. each target had to
be amplified with five different primer pairs to permit
cloning of all vector-insert permutations (constructs
summarized in Figure 2). The pipetting of vector-insert
pairs, co-transformations and plating onto 12-well agar
plates were again performed by the TECAN workstation.
After overnight incubation at 37°C we observed 10-50
colonies per well. In rare cases without colonies the left-
over cells could be spread on 10 cm diameter agar
dishes and then gave a few up to 50 colonies. Over 90%
of the cloning assays resulted in enough colonies to go
on. To stringently test the cloning and expression effi-
ciency, only two colonies per target-vector combination
were picked and grown in 2xTY broth with antibiotics
in 24-well plates. The plasmid preparation was
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performed the next morning on the TECAN work-
station. The resulting DNAs (70-150 ng μL-1) were used
as template for diagnostic PCRs with the same primers
as those for insert amplification. Usually both or at least
one of the clones scored positively in 85% of the cases
(Figure 5). A series of the positive clones was subjected
to restriction mapping which indicated that all clones
were correct. Eight clones were randomly selected and
subjected to DNA sequencing. All of them contained
the expected insert in the proper orientation in the
chosen vector.
During the last two years many cloning experiments
by co-transformation without positive selection have
been performed in our laboratory. In these cases a
Figure 5 Overview of cloning and expression results. All cloning results with the described vectors and targets are summarized. Two
colonies were picked for each vector-target combination and analyzed in order to apply a stringent test to the cloning and expression systems.
Top lanes state vector name and design features; vertical lanes indicate target proteins; shaded lanes indicate experimental results; code see
below; upper lane with cloning result, ie. PCR with insert primers; lower lane with expression result, ie. soluble protein after mini-IMAC target
purification. Positive Test PCR means a clearly visible band of the expected size on agarose gel. Positive for soluble protein means a clearly
visible band on the Coomassie-stained SDS-PAGE at the correct size in the fraction after purification by Ni-NTA column chromatography.
Designations: 1/2 and 2/2 indicate first and second clone that were picked; CapGly, Mr = 10 KDa, CAP-Gly domain 1 of human CLIP170,
accession number NP_002947; EB1, full length of human EB1 protein, Mr = 32 KDa, accession number AAC09471; TTL, Mr = 48 KDa, full length
human tubulin-tyrosin ligase, accession number NP_714923; VP3, Mr = 62 KDa, full length of adeno-associated virus capsid protein 3, accession
number AF043303, synthetic sequence, see ‘Additional file 1’; PKNG, 78 KDa, full length of the M. tuberculosis serine/threonine-protein kinase G,
accession number NP_214924; CLIP170, Mr = 54 KDa, fragment of human CLIP170 fused with a GCN4 sequence, accession number NP_002947.
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success rate of 10-90% was achieved. Thus, these meth-
ods are also suitable for everyday seamless cloning with-
out applying any selection for the correct clones. The
main limitation seems to be the vector and insert length.
The larger the DNAs, the less frequently they will be co-
transformed. Treatment of the PCR products with the
ClonEZ kit increases both the number of colonies and
the rate of success. The SLIC method [14] can be used
as a backup procedure. We suggest using a variant (see
‘Additional file 1’) of the published protocol which is
unreliable in our hands. We feel that in conjunction
with these two rescue methods most standard cloning
applications are covered by the protocols described here.
This means easy seamless cloning with free choice of
the cloning overhangs is now possible at low cost for
the majority of basic cloning experiments. All methods
described in this publication are fully automatable for
high-throughput applications. With well-expressible tar-
gets of less than 1.5 kb length it is sufficient to pick ran-
domly two colonies to reach a 70% success rate in
expression of the target. If a higher success rate is
required, more colonies can be picked. This may be
necessary when cloning target DNA by direct PCR
amplification from libraries [6]. A recently published
method to deplete shorter PCR products in mixtures
[15] may be helpful in these cases.
Expression yields high level of soluble protein
The level of protein expression attained in E.coli cells by
the new vectors (all vectors, except PSAP1) was compar-
able to that observed with typical commercial expression
vectors like pET15, pET28 or pET47 (Figure 4). 80% of
Figure 6 Small scale purification of expression products. The cells of 4 ml culture were pelleted and disrupted by sonification. After
centrifugation the target proteins in the supernatant were purified by automated batch IMAC and run on 12% SDS-PAGE. In each panel, total
protein T, protein in the supernatant S and purified protein P are given. Typical examples of purifications are shown.
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the constructs with insert (Figure 5, Test PCR) yielded
soluble expression of the target protein as demonstrated
by purification of the products by IMAC (Figure 5 and
Figure 6, Soluble Protein). Based on sequencing of a few
expression-negative examples, we assume that mutations
in the regions of the incorporated synthetic primers
account for a large proportion of the negative results.
Discussion
A facile yet reliable way of molecular cloning
Recently, a library with almost 5,000 cDNAs was sub-
cloned into an expression vector by an elaborate seam-
less enzyme-free cloning method [16] using intracellular
DNA recombination. The inserts were PCR-amplified,
gel-purified and mixed with vector that had been linear-
ized by restriction and gel purification. The transforma-
tion of the purified vector plus PCR product into very
highly competent E.coli cells yielded a similar cloning
success rate as achieved in this work. In a later version,
a positive selection was applied that depends on the use
of a specifically engineered cell [3] or a cell with an
intact lacZ reporter gene. Due to the gel purification
step, this method is currently not amenable to automa-
tion. The publication also lacks the demonstration of
target expression. Despite these shortcomings, the
results confirm the usefulness of the approach as
described here.
Automated applications call for robust processes with a
cloning success rate exceeding 80% while co-transforma-
tion cloning usually yields more than 20% correct clones.
Thus, we needed to increase the percentage of correct
clones. To achieve this goal all our direct expression vec-
tors for E.coli employ positive or negative selection.
Judged from our experience with a set of six widely dif-
ferent, but well expressible target genes we conclude that
our vectors perform as well as commercial standard
expression vectors. This is no surprise because the vec-
tors have been built based on well-established vector
backbones. The new element is the positive selection cas-
sette which was introduced by the co-transformation
technique. PCR-amplified activated versions of the cas-
settes can be used for vector construction and later rever-
sion to a selection-negative vector by site-directed
mutagenesis. In this way, most plasmids can be quickly
converted to positive selection vectors. The level of resi-
dual resistance to the selective antibiotic depends on the
copy number of the used plasmids. Hence, we suggest to
titrate the resistance of the vector and to compare it to a
construct which contains a selectable insert.
Conclusions
The increasing demand for genetically engineered pro-
teins prompted others [17] and us to develop a robust,
simple, low-cost approach for rapid target expression
cloning on automated platforms. Most published cloning
systems require in vitro modification of the insert DNA
and the vector DNA with techniques beyond a simple
PCR. The here introduced methods lead to efficient
assembly of direct expression plasmids starting with
purified PCR-products both for the vector and the insert
DNA. The vector and insert PCR products have 13-20
bp long short regions of identity at their respective
ends. No further in vitro steps are required to construct
the expression clones. The recombination of the match-
ing ends occurs inside the transformed E.coli cells. We
have called this process “co-transformation cloning”.
Our results establish co-transformation and positive
selection cloning in conjunction with the provided
vectors and selection cassettes as an alternative to high-
throughput cloning systems like Gateway or ligase-
independent cloning (LIC).
Additional material
Additional file 1: Supplementary materials.
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